Search

A study conducted at Liverpool Hospital in Sydney, Australia, compared the treatment outcomes of metronidazole versus vancomycin for mild to moderate Clostridioides difficile infection in patients with inflammatory bowel disease (IBD). The research found that while metronidazole was effective, it may be associated with higher rates of treatment failure compared to vancomycin. The study included 47 episodes of CDI in 34 patients, with 53% having Crohn's disease, 44% ulcerative colitis, and 3% IBD unclassified. Proton-pump inhibitor therapy was identified as a risk factor for adverse outcomes. [Extracted from the article]

A study conducted by a researcher from Lovely Professional University in Punjab, India, focused on combination therapies for Post-Kala-Azar Dermal Leishmaniasis (PKDL). The study reviewed the efficacy, safety, and tolerability of various drug combinations used in India and Sudan, such as miltefosine-liposomal amphotericin-B and SSG-based combinations. The research highlighted the need for large-scale randomized controlled trials to verify the efficacy and safety of these combination therapies for PKDL. The availability of liposomal amphotericin-B, miltefosine, and immunotherapy shows promise for the clinical management of PKDL. [Extracted from the article]

Researchers from Federal University Jatai conducted a study to evaluate the efficacy of nitazoxanide in treating neurotoxoplasmosis in mice. The study compared nitazoxanide treatment to the standard therapy of pyrimethamine combined with sulfadiazine. While nitazoxanide showed potential, the combination therapy was more effective in controlling neurotoxoplasmosis in the experimental model. This research provides valuable insights into potential treatments for this severe complication of toxoplasmosis. [Extracted from the article]

A study conducted in Casablanca, Morocco, by the Institute Pasteur Maroc found a high prevalence of Helicobacter pylori (H. pylori) infection in Moroccan children, with an overall infection rate of 80.3%. The study also revealed a high resistance rate of 70.8% to metronidazole, especially among pediatric patients living in urban areas. The researchers recommend that antibiotic therapy for H. pylori should be preceded by testing for antibiotic susceptibility to ensure effective treatment. [Extracted from the article]

A recent study conducted by the Postgraduate Institute of Medical Education and Research focused on optimizing the Loop Mediated Isothermal Amplification Assay to detect chloroquine resistance in Plasmodium vivax malaria cases in India. The study found that the assay successfully detected single nucleotide polymorphisms in the Pvmdr1 gene, indicating a trend towards chloroquine resistance in Plasmodium vivax. This research could help identify emerging hubs of drug resistance and inform antimalarial drug policy in the future. [Extracted from the article]

The article discusses a novel therapeutic strategy for Clostridioides difficile infection (CDI) using a combination of Mitomycin C (MMC) and low-dose Metronidazole (MTZ). The study found that MMC synergistically enhances the effectiveness of MTZ in inhibiting the growth of C. difficile, reducing resistance in biofilms, and improving survival rates in a mouse model of CDI. The research suggests that this combined antibiotic treatment could offer a promising new approach to treating CDI. [Extracted from the article]

A study conducted at Thiagarajar College in Tamil Nadu, India, focused on the fabrication of a nanocomposite material containing iron manganese oxide and reduced graphene oxide for the electrochemical detection of metronidazole. The research demonstrated the effectiveness of the nanocomposite in detecting the antibiotic drug with high sensitivity, reproducibility, and stability. The study concluded that the fabricated nanocomposite could be used for the accurate determination of antibiotic drugs in real sample analysis, showing promise for environmental applications. The research was supported by various institutions and has been peer-reviewed, providing valuable insights into the field of nanotechnology and electrochemical sensing. [Extracted from the article]

A study conducted at Yokohama City University in Japan focused on a fourth-line eradication therapy for Helicobacter pylori using a regimen of vonoprazan, high-dose amoxicillin, clarithromycin, and metronidazole based on susceptibility testing. The study included 20 patients who had previously failed eradication therapies and found that the susceptibility-testing-based fourth-line eradication therapy had an eradication rate of 63.2% in intent-to-treat analysis and 70.6% in per-protocol analysis. The research suggests that this modified concomitant therapy could be a potential option for Helicobacter pylori eradication after previous treatment failures. [Extracted from the article]

Researchers at Sichuan Agricultural University in Ya'an, China, conducted a study on carbon-based nanostructures for the delivery and detection of the drug metronidazole. The study found that fullerene (C60) had stronger interactions with metronidazole compared to carbon nanotube (CNT) and carbon nanosheet (CNS). The research suggests that carbon-based nanomaterials have potential applications in the delivery and detection of metronidazole, with CNS showing better sensing performance. This work was supported by the Natural Science Foundation of Sichuan Province and has been peer-reviewed. [Extracted from the article]

Researchers at the University of Porto in Portugal have conducted a study on the efficacy of chloroquine-derived bile salts in pluronic F127 micelles against blood-stage Plasmodium falciparum, the parasite that causes malaria. The study found that these salts, when loaded into polymeric micelles, showed enhanced antiplasmodial efficacy, with a significant decrease in IC50 values. This research opens up new possibilities for the nanoformulations of antimalarial compounds and was supported by the NIH National Institute of Allergy & Infectious Diseases. [Extracted from the article]

Researchers at the University of Porto have published a study on the efficacy of chloroquine-derived bile salts in Pluronic F127 micelles against blood-stage Plasmodium falciparum, the parasite responsible for malaria. The study explores the use of polymeric micelles as nanovehicles for delivering antimalarial drugs, showing promising results in enhancing the antiplasmodial efficacy of the compounds. This research, supported by the NIH National Institute of Allergy & Infectious Diseases, offers new possibilities for nanoformulations of antimalarial compounds. [Extracted from the article]

A study conducted by researchers at Jimma University in Ethiopia evaluated the in vivo efficacy of chloroquine (CQ) and primaquine (PQ) combination therapy against uncomplicated Plasmodium vivax malaria. The study, which took place in the Limu Kossa District, Southwest Ethiopia, involved 108 patients who received the treatment regimen and were monitored for 42 days. Results showed a 100% cure rate at both day 28 and day 42, indicating excellent therapeutic efficacy. The researchers emphasized the importance of patient adherence to the full course of PQ treatment to preserve this efficacy. [Extracted from the article]

A clinical trial, NCT06640439, conducted at Huashan Hospital, focuses on LED therapy using 830 nm in mandibular third molar surgery. The trial aims to assess the efficacy of LED therapy in reducing pain, swelling, and trismus post-surgery, with a primary completion date set for February 14, 2025. The study includes detailed information on the intervention model, study arms, recruitment criteria, and administrative details, emphasizing the importance of photobiomodulation therapy and antibiotic use in the treatment protocol. [Extracted from the article]

A study conducted at the Affiliated Jiangmen Hospital of Sun Yat-sen University explored the potential of amodiaquine therapy in ameliorating stress-induced premature cellular senescence by promoting SIRT1-mediated HR repair. The research highlighted the importance of DNA repair mechanisms in combating cellular senescence and aging-related diseases. Amodiaquine was found to significantly enhance HR repair and delay the onset of stress-induced premature cellular senescence through a SIRT1-dependent pathway. This study opens up possibilities for identifying compounds that target DNA repair for therapeutic purposes in aging-related conditions. [Extracted from the article]

Researchers at Universidad Arturo Prat in Chile conducted a study on the green synthesis of phenylaminonaphthoquinones to explore their antibacterial and antiparasitic properties. The study involved in silico PASS predictions and in vitro evaluation of the synthesized compounds against bacterial and Plasmodium strains. The research also included docking studies to understand the compounds' action and ADMET predictions for further insights. This study contributes to the potential application of these compounds in drug discovery and development. [Extracted from the article]

Researchers at the Affiliated Suzhou Hospital of Nanjing Medical University in China conducted a study on Helicobacter pylori (Hp) infection and drug resistance. They found high rates of resistance to metronidazole, levofloxacin, and clarithromycin among Hp strains. Factors such as age, previous Hp eradication history, and drinking water source were associated with drug resistance. The study emphasizes the importance of individualized treatment and antibiotic selection for Hp eradication. [Extracted from the article]

A recent study conducted at Balikesir University Faculty of Medicine investigated the antitrichomonal activity of cinnamaldehyde, carvacrol, and thymol, as well as their synergy with metronidazole in treating Trichomonas vaginalis infections. The research found that these essential oil components exhibited strong activity against T. vaginalis isolates and showed a synergistic interaction with metronidazole, potentially reducing drug side effects and resistance development. This study provides valuable insights into alternative treatment options for parasitic infections, particularly in cases of metronidazole resistance. [Extracted from the article]

A recent study conducted at a British University explores the synergistic efficacy of ZnO quantum dots, Ag NPs, and nitazoxanide composite in combating multidrug-resistant human pathogens. The research highlights the potential of this composite as a new approach to revolutionizing antimicrobial treatment, showcasing significant therapeutic efficacy levels against MDR infections. This innovative combination has not been previously addressed in published literature, offering a promising avenue for addressing antibiotic resistance and enhancing global health outcomes. [Extracted from the article]

New research from the National Institute for Communicable Disease Control and Prevention in Beijing, China, has developed a rapid antimicrobial susceptibility test for Helicobacter pylori, a Gram-negative bacterium. The study found that the test, which uses Raman microspectroscopy, accurately determined the susceptibility of H. pylori to metronidazole, a commonly used antibiotic. The test also revealed distinct mechanisms in bacterial responses to metronidazole. The researchers suggest that this method could guide metronidazole prescriptions for H. pylori eradication and aid in rapid screening for drug resistance. [Extracted from the article]

A recent study conducted by Heidelberg University in Germany has explored the potential use of the drug Nitazoxanide for the treatment of lymphangioleiomyomatosis (LAM), a rare genetic lung disease. The current treatment for LAM, the mTORC1 inhibitor Rapamycin, only slows disease progression and often produces incomplete responses. Nitazoxanide, an antiprotozoal drug, has shown an inhibitory effect on mTORC1 in human cell lines and has a long history of safe clinical use. The study found that Nitazoxanide reduced cell growth in LAM cell lines and had a pronounced effect on reducing pAkt. However, the results of the study in a mouse model were inconclusive. Further research is needed to determine the potential of Nitazoxanide as a treatment for LAM. [Extracted from the article]

A recent report from Shanghai Jiao Tong University School of Medicine discusses the potential therapeutic efficacy of tinidazole mouth rinse for the treatment of oral lichen planus (OLP). The study involved a pilot study with 27 OLP patients who used thrice-daily tinidazole mouth rinse for one week. The results showed a significant decrease in visual analog scale (VAS) scores for both reticular and erosive OLP patients, as well as a decrease in the abundance of Fusobacterium nucleatum on the damaged mucosa surface. The researchers concluded that tinidazole mouth rinse could be a viable local therapeutic option for OLP, but further randomized controlled studies are needed to confirm these findings. [Extracted from the article]

A recent report from Ladoke Akintola University of Technology highlights the ongoing issue of malaria in Africa, with Plasmodium falciparum being the main cause of severe cases. The emergence of drug-resistant strains, particularly those associated with the pfcrt gene mutations, has hindered efforts to control malaria. These mutations, such as the K76T mutation, have compromised the effectiveness of chloroquine, a once vital antimalarial drug. The study emphasizes the need for a comprehensive approach to address the challenges posed by these mutations, including enhanced surveillance, innovative drug development, and community education. Continued research and investment are crucial for overcoming resistance and achieving success in malaria control and eradication in Africa. [Extracted from the article]

This document provides information about a clinical trial being conducted by the Johns Hopkins Bloomberg School of Public Health and the National Institute of Allergy and Infectious Diseases. The trial aims to determine if nitazoxanide can effectively treat Cryptosporidium infection in malnourished children aged 6-12 months in Bangladesh. The trial will compare nitazoxanide to a placebo and participants will take the medication or placebo for 3 days, provide blood and urine samples, and receive regular visits from research assistants. The trial is currently in the interventional phase and is expected to be completed by November 2028. [Extracted from the article]

A recent study conducted by researchers at the Ocean University of China in Qingdao investigated the use of a carbon black-polytetrafluoroethylene (C-PTEE) cathode to degrade metronidazole (MNZ) in wastewater. The researchers optimized the performance and operating conditions of the cathode through experiments. They found that reactive oxygen species (ROS) generated by electrolytes in the NaCl and Na2SO4 systems were more effective in removing MNZ compared to the NaNO3 system. The study also proposed three possible degradation paths for MNZ and evaluated the energy consumption of the system. This research provides valuable insights for the industrial-scale application of MNZ wastewater treatment. [Extracted from the article]

Researchers from Shiraz University in Iran have developed a sustainable material called MACC-N, which is derived from Prunus scoparia shells and consists of Fe3O4 nanoparticles supported on chemically functionalized carbon. This material was found to be effective in removing toxic pharmaceuticals, specifically metronidazole and acetaminophen, from water. The MACC-N exhibited desirable surface properties and reactive functional groups, allowing for efficient adsorption of the pharmaceuticals. The research suggests that MACC-N could be a viable alternative to traditional wastewater treatment methods on a commercial scale. [Extracted from the article]

Researchers at Nankai University in Tianjin, China have developed a metal-organic framework (MOF) flexible sensor that can detect the antibiotic metronidazole (MNZ) in water. MNZ is commonly used to treat bacterial infections in humans and animals, but its misuse can pose a threat to human health. The synthesized MOF, called TDA-Tb, demonstrated selective and sensitive detection of MNZ, with a low limit of detection. The researchers also created a flexible sensor, TDATb-M, incorporating TDA-Tb into membrane materials for convenient usage. This development could inspire the creation of more probes with wide application ranges. [Extracted from the article]

A recent study conducted at Jinan Third People's Hospital in Shandong, China, examined the impact of combining antibiotics with non-surgical periodontal therapy. The study found that adding systemic antibiotics to non-surgical intervention resulted in a significant reduction in probing pocket depth (PPD). Additionally, the use of topical antimicrobial agents, specifically doxycycline, showed a beneficial impact on reducing PPD. The study concluded that the combination of adjuvant systemic and topical antimicrobial therapy with non-surgical periodontal therapy can have positive effects on PPD and clinical attachment level (CAL). [Extracted from the article]

A recent study conducted at the University of Baghdad in Iraq explored the use of bioadhesive vaginal films as a potential treatment for vaginal infections. The researchers prepared and characterized different formulas of tinidazole films using various polymeric combinations. The films were evaluated for their physicochemical characteristics, drug release, mucoadhesive strength, and swelling. The study concluded that two specific formulas showed promising results in terms of flexibility, mucoadhesive strength, and prolonged drug release, suggesting their potential as a delivery system for tinidazole in the treatment of vaginal infections. [Extracted from the article]

A preprint abstract reports on a randomized controlled trial comparing the efficacy of a novel maxillofacial drug delivery technology with oral administration of metronidazole. The study examined patients with acute pulpitis in relation to maxillary molars and divided them into two groups. The results showed that the maxillofacial route group had a higher presence of the drug compared to the oral route group. The study suggests that the maxillofacial drug delivery technique could be an effective alternative for painless and controlled drug delivery. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]

Researchers from South Valley University in Qena, Egypt have developed an eco-friendly and inexpensive electrochemical sensor for detecting the antibiotic metronidazole (MET). The sensor, made from a CaO-Chitosan nanocomposite, showed higher electrocatalytic activity compared to an unmodified electrode. The sensor was able to detect MET in commercial tablets and milk samples, and demonstrated good stability and repeatable response. This research provides a novel and cost-effective method for detecting antibiotics in various samples. [Extracted from the article]

A study conducted by researchers at the National Institute of Technology Silchar has developed a novel photocatalyst called CSHK-Ni, which is a nanocomposite of CuS, HKUST-1 MOF, and Ni(acac)2 metal complex. This photocatalyst has shown remarkable efficiency in degrading nitroimidazole-containing antibiotics, Tinidazole and Metronidazole, under visible light exposure. The study also examined the removal of chemical oxygen demand (COD) and total organic carbon (TOC) in wastewater. The research concludes that CSHK-Ni has the potential to be an effective and environmentally friendly method for eliminating pharmaceutical pollutants. [Extracted from the article]

Researchers at the SRM Institute of Science and Technology in Tamil Nadu, India have developed a new method for detecting the antimalarial drug Amodiaquine (ADD) using a composite material called Dy-MOF@MWCNT/GC. The composite material was prepared using a sonochemical process and ultrasonication. The researchers found that the Dy-MOF@MWCNT/GC electrode showed good electrocatalytic activity for the detection of ADD, with a broad linear range and low limit of detection. This research provides a potential method for detecting ADD in human urine samples. [Extracted from the article]

The article provides information on a patent application for treatment using an antiviral compound and nitazoxanide, filed by the inventor Theodore Henderson on May 28, 2024 and was made available online on August 29, 2024. Topics discussed include background information supplied by the inventors about virally induced functional disorders (VIFD), inventor's summary information for the patent application, and the claims supplied by the inventors.

A recent study conducted at Massachusetts General Hospital in Boston has identified a potential cause of Leigh syndrome, a fatal mitochondrial disease in children. The researchers found that mutations in the gene encoding sulfide:quinone oxidoreductase (SQOR), a mitochondrial protein, were linked to Leigh syndrome. Mice with a mutation in the SQOR gene exhibited symptoms of Leigh syndrome, including increased blood lactate levels and impaired complex IV activity. The researchers discovered that treatment with metronidazole, an antibiotic, or a sulfur-restricted diet improved the symptoms and prolonged the survival of the mice. These findings suggest that targeting SQOR could be a potential therapeutic approach for treating Leigh syndrome in humans. [Extracted from the article]

A recent study conducted by researchers at the Federal University of Goias in Brazil has developed an eco-friendly method for quantifying the drug tinidazole in tablets. Tinidazole is commonly prescribed for the treatment of giardiasis, trichomoniasis, and amoeba infections. The researchers aimed to develop a method that adheres to the principles of Green Analytical Chemistry (GAC), which include generating less waste, using less toxic reagents and solvents, and assessing costs involved. The proposed method, which uses spectrophotometry in the ultraviolet region, was found to be precise, selective, and robust. Additionally, it was deemed a green alternative according to the Eco-Scale Assessment (ESA). [Extracted from the article]

Researchers at Tulane University are conducting a five-year study funded by a $9.2 million National Institutes of Health grant to find a more effective treatment for trichomoniasis, the most common curable sexually transmitted infection (STI) worldwide. The study will compare the effectiveness of a recently approved medication, secnidazole, with the current standard treatment, metronidazole, using a 1,200-person cohort across Louisiana, Alabama, and Florida. Trichomoniasis, caused by the parasite trichomonas vaginalis, infects about 156 million people annually and is associated with a higher susceptibility to HIV and adverse outcomes in pregnancy. The study aims to improve treatment options and increase awareness to encourage more screening for trichomoniasis. [Extracted from the article]

The article focuses on a clinical trial evaluating the effectiveness of a combination of antibiotics (cephalosporin 3rd generation, clarithromycin, metronidazole) in prolonging pregnancies complicated by previable threatened labor with intact membranes. Topics include assessing neonatal outcomes, maternal morbidity, and bacteriological impacts, as well as comparing this antibiotic regimen to standard treatments.

The article presents new research from the University of Sao Paulo evaluating the effectiveness of metronidazole in gel and film forms for treating periodontitis after scaling and root planning. Topics discussed include the clinical trial design involving different treatment groups, the evaluation of periodontal health improvements through various clinical parameters, and the conclusion that both therapies significantly enhance periodontal health compared to standard treatment alone.